APGE
Apogee Therapeutics, Inc.
$83.03
+1.49%
2026-05-08
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Key Fundamentals
Forward P/E
-15.26
EPS (TTM)
$-4.22
ROE
-31.6%
Profit Margin
0.0%
Debt/Equity
0.98
Price/Book
6.27
Beta
0.69
Market Cap
$6.24B
Avg Volume (10D)
580K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$95.32
60D Low
$65.22
Avg Volume
854K
Latest Close
$83.03
Get breakout alerts for APGE
Sign up for Breakout Scanner to receive daily notifications when APGE triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Apogee Therapeutics, Inc. (APGE) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors APGE daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. APGE operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.